Arbutus Biopharma CorporationABUSNASDAQ
LOADING
|||
Year-over-year gross profit growth rate
| Period | Value |
|---|---|
| Q3 2025 | -95.18% |
| Q2 2025 | 249.26% |
| Q1 2025 | 0.57% |
| Q4 2024 | -640.40% |
| Q3 2024 | -22.42% |
| Q2 2024 | 12.66% |
| Q1 2024 | 109.94% |
| Q4 2023 | -431.02% |
| Q3 2023 | 0.15% |
| Q2 2023 | -30.45% |
| Q1 2023 | 140.03% |
| Q4 2022 | -380.65% |
| Q3 2022 | -58.21% |
| Q2 2022 | 13.19% |
| Q1 2022 | 178.60% |
| Q4 2021 | -579.22% |
| Q3 2021 | 124.80% |
| Q2 2021 | -15.43% |
| Q1 2021 | 16.69% |
| Q4 2020 | -32.86% |
| Q3 2020 | -17.77% |
| Q2 2020 | -0.29% |
| Q1 2020 | 17.36% |
| Q4 2019 | 26.38% |
| Q3 2019 | -21.37% |
| Q2 2019 | 13.87% |
| Q1 2019 | -49.53% |
| Q4 2018 | 37.35% |
| Q3 2018 | 0.88% |
| Q2 2018 | -20.77% |
| Q1 2018 | 18.15% |
| Q4 2017 | -76.84% |
| Q3 2017 | 39.99% |
| Q2 2017 | -5.64% |
| Q1 2017 | 21.41% |
| Q4 2016 | -15.95% |
| Q3 2016 | -0.39% |
| Q2 2016 | -18.86% |
| Q1 2016 | -465.42% |
| Q4 2015 | 81.95% |